EGFR and non-small cell lung carcinoma: Since the advent of the use of tyrosine kinase inhibitors for the treatment of patients with advanced NSCLC with epithelial growth factor receptor (EGFR) mutations, a new era has emerged in which various molecular therapeutic targets are being studied at the protein and gene levels.